Healthcare Market Report Anti-Adhesion Products 2023

1.1 Purpose
1.2 Suggestion for Best Use
1.3 Scope
1.4 Market Segmentation
1.5 Research Methods
1.5.1 Desk Research
1.5.2 Primary Research
1.6 Analytic and Projection Methods of Market Size
1.6.1 Data Sources
1.6.2 Exchange Rate
1.6.3 Market Size Estimation Methods
1.6.3.1 Reimbursement Size Estimation Methods

3.1 Market Size at Manufacturers/Importers' Initial Selling Prices
3.1.1 Five-Year Forecast of Market Size
3.2 Market Size at Medical Institutions' Purchase Prices
3.2.1 Reimbursement Volume of Anti-Adhesion Products
3.2.1.1 Reimbursement Volume by Medical Department
3.2.1.2 Reimbursement Volume by End-User Type
3.2.2 Reimbursement Volume by Physical State of Product
3.2.2.1 Reimbursement Volume by Physical State of Product & Medical Department
3.2.2.2 Reimbursement Volume by Physical State of Product Category & End-User Type

4.1 GC Biopharma
4.2 Dalim Tissen
4.3 Medtronic
4.4 Baxter
4.5 Samyang Holdings
4.6 CG Bio
4.7 Shinpoong Pharm
4.8 LG chem
4.9 Genewel
4.10 BNC Korea
4.11 CareRex
4.12 BMI Korea
4.13 Johnson & Johnson Medical

5.1 Impact of COVID-19
5.2 Characteristics of Healthcare Market in Korea
5.2.1 History of Anti-Adhesion Products
5.2.2 Change History of Payment Environment
5.2.3 Number of Medical Institutions in Korea
5.2.4 Determination Criteria for Reimbursement vs. Non-Reimbursement
5.3 Key Indicators of Anti-Adhesion Market
5.3.1 Rising Costs and Competition for More Beds
5.3.2 Aging Population
5.3.3 Number of Surgical Operations
5.3.4 Number of Laparoscopic Procedures
5.3.5 Obstetrics and Gynecology Treatments and Surgical Operations
5.3.6 Urology Treatments
5.3.7 Orthopedic Treatments and Surgical Operations
5.3.8 Otolaryngology / Internal Medicine Treatments and Surgical Operations
5.3.9 Seven Diagnosis-Related Groups
5.4 Market Drivers
5.4.1 Demand
5.4.2 Increase in Number of Suppliers
5.5 Market Opportunities
5.5.1 Rising Demand with Surgical Operations
5.5.2 Reimbursement Coverage Expansion Policy
5.5.3 Reimbursement of Medical Devices as Product Fees in the Seven DRG Payment Scheme
5.5.4 Clinical Trials on New Anti-Adhesion Technologies
5.6 Market Restraints
5.6.1 Reimbursement Pricing Scheme of National Health Insurance
5.6.2 Concentration of Specific Physical States
5.7 Unmet Needs

Appendix 1 Reimbursement Volume of Postoperative Anti-Adhesion Products (2016-2020)
Appendix 2 Major Products Included in This Report for Market Estimation (As of 01 March 2023)
Appendix 3 Products for Anti-Adhesion Market Research (As of 01 March 2023)